Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14378317 | 0.80 | HRH3 (0.33) | HRH3CYP2D6KCNH2CHRNA7KDM1A | |
| SCHEMBL22566191 | 0.77 | HRH3 (0.36) | HRH3CYP2D6KCNH2 | |
| SCHEMBL20715134 | 0.76 | HRH3 (0.32) | HRH3CYP2D6KCNH2CHRNA7KDM1A | |
| SCHEMBL23262825 | 0.74 | — | — | |
| SCHEMBL12909477 | 0.73 | HRH3 (0.33) | HRH3CYP2D6KCNH2CHRNA7KDM1A | |
| SCHEMBL21482205 | 0.73 | HRH3 (0.33) | HRH3CYP2D6KCNH2 | |
| SCHEMBL3538716 | 0.72 | HRH3 (0.38) | HRH3CYP2D6KCNH2CHRNA7KDM1A | |
| SCHEMBL21191898 | 0.71 | — | — | |
| SCHEMBL24671073 | 0.71 | ALDH1A1 (0.38) | HRH3CYP2D6KCNH2CHRNA7KDM1A | |
| SCHEMBL12890613 | 0.70 | HRH3 (0.39) | HRH3CYP2D6KCNH2CHRNA7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190315747-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315747-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK3, CDK13, CDK1 | HRH3 1444/4885CYP2D6 615/4885KCNH2 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.